Artisan Partners Limited Partnership lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.5% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,962,480 shares of the biopharmaceutical company’s stock after buying an additional 29,252 shares during the period. Regeneron Pharmaceuticals makes up approximately 1.8% of Artisan Partners Limited Partnership’s portfolio, making the stock its 12th biggest holding. Artisan Partners Limited Partnership owned 1.86% of Regeneron Pharmaceuticals worth $963,852,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Oppenheimer & Co. Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 20.6% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 7,007 shares of the biopharmaceutical company’s stock worth $3,441,000 after buying an additional 1,199 shares during the last quarter. Dupont Capital Management Corp purchased a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $220,000. Blair William & Co. IL lifted its stake in Regeneron Pharmaceuticals by 4.8% in the second quarter. Blair William & Co. IL now owns 1,713 shares of the biopharmaceutical company’s stock valued at $841,000 after purchasing an additional 79 shares during the last quarter. National Pension Service lifted its stake in Regeneron Pharmaceuticals by 10.8% in the second quarter. National Pension Service now owns 66,518 shares of the biopharmaceutical company’s stock valued at $33,920,000 after purchasing an additional 6,481 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its stake in Regeneron Pharmaceuticals by 2.4% in the second quarter. Principal Financial Group Inc. now owns 115,201 shares of the biopharmaceutical company’s stock valued at $56,580,000 after purchasing an additional 2,646 shares during the last quarter. Hedge funds and other institutional investors own 67.96% of the company’s stock.
In other Regeneron Pharmaceuticals news, SVP Robert E. Landry sold 663 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $498.60, for a total value of $330,571.80. Following the sale, the senior vice president now directly owns 10,099 shares in the company, valued at approximately $5,035,361.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Michael S. Aberman sold 2,269 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $532.42, for a total transaction of $1,208,060.98. Following the completion of the sale, the senior vice president now owns 9,193 shares in the company, valued at $4,894,537.06. The disclosure for this sale can be found here. Over the last quarter, insiders sold 99,543 shares of company stock worth $47,831,369. 10.40% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY WARNING: “Regeneron Pharmaceuticals, Inc. (REGN) Shares Bought by Artisan Partners Limited Partnership” was published by Equities Focus and is the sole property of of Equities Focus. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.equitiesfocus.com/2017/09/17/regeneron-pharmaceuticals-inc-regn-shares-bought-by-artisan-partners-limited-partnership.html.
Regeneron Pharmaceuticals, Inc. (REGN) traded down 1.77% on Friday, reaching $433.45. The company had a trading volume of 1,002,422 shares. The stock’s 50 day moving average price is $472.80 and its 200-day moving average price is $445.37. The stock has a market capitalization of $45.96 billion, a PE ratio of 43.48 and a beta of 1.65. Regeneron Pharmaceuticals, Inc. has a 12-month low of $325.35 and a 12-month high of $543.55.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.67 by $1.50. The company had revenue of $1.47 billion for the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. Regeneron Pharmaceuticals’s revenue for the quarter was up 21.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.82 EPS. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post $14.90 earnings per share for the current fiscal year.
Several equities analysts recently commented on the company. Leerink Swann reiterated an “outperform” rating and issued a $573.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 22nd. Raymond James Financial, Inc. reiterated an “outperform” rating and issued a $547.00 price objective (up previously from $475.00) on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 22nd. Bank of America Corporation reiterated a “buy” rating and issued a $593.00 price objective (up previously from $589.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, July 21st. BMO Capital Markets reiterated a “market perform” rating and issued a $484.00 price objective (up previously from $421.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, July 21st. Finally, Sanford C. Bernstein downgraded Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating and upped their price objective for the company from $410.00 to $480.00 in a research note on Monday, June 26th. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the stock. Regeneron Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $491.43.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.